Sign in Subscribe
Diseases

Chronic Obstructive Pulmonary Disease (COPD) Market Outlook

Strategic Insights

— 2 min read

The chronic obstructive pulmonary disease (COPD) market is expected to experience consistent growth, with the market valued at USD 16,075 million in 2023 and projected to increase by 2034. The disease affects men and women worldwide, causing abnormalities in the lungs' small airways, leading to limitation of airflow in and out of the lungs. Effective therapy is available to control symptoms, slow progression, reduce the risk of complications and exacerbations, and improve the ability to lead an active life.

Key Takeaways:

  • The total diagnosed prevalent cases of COPD in the 7MM were approximately 44.2 million in 2023, with the United States exhibiting the highest diagnosed prevalent population of COPD.
  • The total diagnosed prevalent cases of COPD in the US were around 18.3 million in 2023 and are projected to increase during the forecast period owing to the increasing prevalence of smoking, improved diagnosis, and increasing awareness among the patient population.
  • The leading COPD companies are Genentech, Inc., GlaxoSmithKline, Verona Pharma plc, Regeneron Pharmaceuticals, Sanofi, MedImmune LLC, EpiEndo Pharmaceuticals, Tetherex Pharmaceuticals, AstraZeneca, Chiesi Farmaceutici S.p.A., Synairgen Research Ltd., Mereo Biopharma, Organicell Regenerative Medicine, Pulmotect, Inc., Inmunotek S.L., PULMATRiX, GLENMARK PHARMACEUTICALS LTD, Dimerix Limited, ProterixBio, and others.
  • Promising COPD therapies include Astegolimab (MSTT1041A, AMG 282, RG6149), SB240563 (Mepolizumab)/NUCALA, Ensifentrine (RPL554), Itepekimab/SAR440340/REGN3500, Dupilumab/SAR231893 (Dupixent), Tozorakimab (MEDI3506), FASENRA (Benralizumab), Tezspire (Tezepelumab), EP395, SelK2, Mitiperstat (AZD4831), CHF6001/Tanimilast, SNG001 (IFN-?), Acumapimod (BCT-197), Zofin, PUL-042, MV130, GSK3923868, PUR1800, GRC 39815, DMX-700, and others.

Statistics:

  • Total diagnosed prevalent cases of COPD in the 7MM: approximately 44.2 million in 2023.
  • Total diagnosed prevalent cases of COPD in the US: around 18.3 million in 2023.
  • Total diagnosed prevalent cases of COPD in EU4 and the UK: around 18.6 million in 2023.
  • Total diagnosed prevalent cases of COPD in Japan: around 7.2 million in 2023.
  • Gender-specific cases of COPD in the UK: ~1.7 million for females and ~2 million for males in 2023.
  • Age-specific cases of COPD: categorized into 18-44 years, 45-54 years, 55-64 years, 65-74 years, and 75+ years.

Sources:

  • M2 COMMUNICATIONS RDATE: 10062025.
  • DelveInsight's report: "Chronic Obstructive Pulmonary Disease Market Insights, Epidemiology, and Market Forecast - 2034."
  • DelveInsight's analyst estimate: approximately 44.2 million diagnosed prevalent cases of COPD in 2023 in the 7MM.
  • DelveInsight's report: "Chronic Obstructive Pulmonary Disease Market Insights, Epidemiology, and Market Forecast - 2034."
  • Genentech Inc. announcement: study will evaluate the efficacy, safety, and pharmacokinetics of astegolimab in combination with standard of care chronic obstructive pulmonary disease (COPD) maintenance therapy in patients with COPD who are former or current smokers and have a history of frequent exacerbations.
  • Areteia Therapeutics study: assessing the PD of dexpramipexole 150 mg twice daily (BID) in participants with eosinophilic COPD.
  • DelveInsight's report: "Chronic Obstructive Pulmonary Disease Market Insights, Epidemiology, and Market Forecast - 2034."
  • DelveInsight's analyst estimate: approximately 44.2 million diagnosed prevalent cases of COPD in 2023 in the 7MM.
  • DelveInsight's report: "Chronic Obstructive Pulmonary Disease Market Insights, Epidemiology, and Market Forecast - 2034."

Read more